Department of Biochemistry, School of Pharmacy, Hacettepe University, 06100, Ankara, Turkey.
Eur J Pharmacol. 2019 Aug 5;856:172415. doi: 10.1016/j.ejphar.2019.172415. Epub 2019 May 24.
Alzheimer's disease (AD), which is predicted to affect 1 in 85 persons worldwide by 2050, results in progressive loss of neuronal functions, leading to impairments in memory and cognitive abilities. As being one of the major neuropathological hallmarks of AD, senile plaques mainly consist of amyloid-β (Aβ) peptides, which are derived from amyloid precursor protein (APP) via the sequential cleavage by β- and γ-secretases. Although the overproduction and accumulation of Aβ peptides are at the center of AD research, the new discoveries point out to the complexity of the disease development. In this respect, it is crucial to understand the processing and the trafficking of APP, the enzymes involved in its processing, the cleavage products and their therapeutic potentials. This review summarizes the salient features of APP processing focusing on APP, the canonical secretases as well as the novel secretases and the cleavage products with an update of the recent developments. We also discussed the intracellular trafficking of APP and secretases in addition to their potential in AD therapy.
阿尔茨海默病(AD)预计到 2050 年将影响全球每 85 人中的 1 人,其导致神经元功能的进行性丧失,导致记忆和认知能力受损。作为 AD 的主要神经病理学标志之一,老年斑主要由淀粉样蛋白-β(Aβ)肽组成,这些肽通过β-和γ-分泌酶的顺序切割从淀粉样前体蛋白(APP)中衍生而来。尽管 Aβ肽的过度产生和积累是 AD 研究的中心,但新的发现指出了疾病发展的复杂性。在这方面,了解 APP 的加工和运输、参与其加工的酶、切割产物及其治疗潜力至关重要。本综述总结了 APP 加工的显著特征,重点介绍了 APP、经典分泌酶以及新型分泌酶和切割产物,并更新了最新的发展情况。我们还讨论了 APP 和分泌酶的细胞内运输以及它们在 AD 治疗中的潜力。